American Society of Hirudotherapy

Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties

Review published in Haematologica (2025)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentSalivary PharmacologyVan Thillo et al. · Haematologica, 2025

Abstract

Treatment options for patients with hemophilia and other bleeding disorders have advanced dramatically over the last few years, not only with the availability of safer factor concentrates, but also with the introduction of factor VIII-mimicking agents. Until recently, there were still areas of hemophilia care that required attention and optimization, including the need for repeated venipuncture, often requiring a central venous access device, and the possible development of inhibitors that limit the efficacy of factor replacement, thereby increasing the complexity and burden of therapy. A new class of rebalancing agents aims to address these remaining issues by inhibiting various natural anticoagulants. Fitusiran is a small interfering RNA agent that reduces antithrombin synthesis in hepatocytes, favoring a procoagulant state. Other promising rebalancing agents are concizumab and marstacimab, which selectively bind to the K2 domain of the tissue factor pathway inhibitor, thus restoring thrombin generation. SerpinPC is a subcutaneous biological inhibitor that blocks the anticoagulant activated protein C pathway, while VGA039 is a monoclonal antibody that targets its cofactor protein S. Although the available clinical data are promising, several important challenges remain. These include the thrombotic risk of rebalancing agents, perioperative and bleeding management, availability in low-income countries, efficacy and factor VIII equivalence compared to existing treatments, ideal target populations, and potential application in other hemostatic disorders. The primary aim of this review is to summarize the best available evidence on these novel rebalancing agents, while highlighting the unknowns, and emphasizing the uncertainties that lie ahead.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansHemophilia AFactor VIIIAntibodies, Monoclonal, HumanizedDisease Management

Summary

This review summarizes rebalancing agents for hemophilia - fitusiran, concizumab, marstacimab, SerpinPC and VGA039 - which inhibit natural anticoagulants to restore thrombin generation, and outlines remaining uncertainties including thrombotic risk, perioperative management and access in low-income countries.

Why This Matters for Hirudotherapy

This review summarizes rebalancing agents for hemophilia and related bleeding disorders, including fitusiran (reducing antithrombin synthesis), concizumab and marstacimab (binding tissue factor pathway inhibitor), SerpinPC (blocking the activated protein C pathway), and VGA039 (targeting protein S), while noting unresolved issues such as thrombotic risk and optimal patient selection. The abstract is relevant to hemostasis and anticoagulant-pathway biology in a hematology context. However, it does not mention leeches, hirudin, leech-derived anticoagulants, or hirudotherapy at any point. Consequently, it provides no direct evidence regarding leech therapy or the leech secretome, and no leech-related relevance should be inferred.

Citation

Reference (Vancouver style)

Van Thillo Q, Hermans C. Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties. Haematologica. 2025;110(12):2902-2912. doi:10.3324/haematol.2025.288245. PMID: 40820726

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.